Methods of treating liver disorders or lipid disorders with a thr-beta agonist

A method of treating a lipid disorder in a subject in need thereof, the method comprising:

• (a) performing a first biomarker test on a first biological sample obtained from the subject, wherein the first biomarker test measures a first expression level of a biomarker, the biomarker being sex hormone-binding globulin (SHBG);
• (b) administering a first dose of 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (“Compound A”) to the subject daily for a first period of time;
• (c) performing a second biomarker test on a second biological sample obtained from the subject, wherein the second biomarker test measures a second expression level of SHBG;
• (d) determining a change or degree of change in the expression level of SHBG based on the results in steps (a) and (c), wherein the change or degree of change is indicative of the subject's sensitivity to Compound A;
• and
• (e) administering a second dose of Compound A to the subject for a second period of time based on the sensitivity result from step (d).